Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;21(8):983-990.
doi: 10.1080/14712598.2021.1931679. Epub 2021 Jun 9.

Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis

Jennifer Clay Cather  1   2 , Chaney T Young  1 , Melody S Young  1   2 , J Christian Cather  2
Affiliations
Review

Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis

Jennifer Clay Cather et al. Expert Opin Biol Ther. 2021 Aug.

Abstract

Introduction: Ixekizumab (IXE), a high affinity humanized monoclonal antibody that selectively targets interleukin-17A, is approved in the United States (US) and the European Union (EU) for pediatric patients with moderate to severe plaque psoriasis. This review summarizes ixekizumab use in the phase 3, randomized, double-blind, placebo-controlled study in pediatric patients with moderate to severe plaque psoriasis and provides some clinical pearls we have learned after using the drug in the pediatric population for the past 3 years.Areas covered: Review of IXORA-PEDS trial data, general literature review pertaining to the systemic treatment of pediatric psoriasis as well as our clinical experience with IXEExpert opinion: IXE is the only IL17 antagonist for pediatric psoriasis and is a welcome addition to our armamentarium.

Keywords: IXORA-PEDS trial; Pediatric psoriasis; expert opinion; ixekizumab.

PubMed Disclaimer

LinkOut - more resources